2024
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscapeThe Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2023
Abstract B030: Form and function in intratumoral immune organization: Understanding the cellular composition of TCF1+ CD8+ T cell niches in human cancer
Jansen C, Vo B, Sobierajska E, Greenwald R, Mullane P, Prokhnevska N, Cardenas M, Bilen M, Osunkoya A, Master V, Kissick H. Abstract B030: Form and function in intratumoral immune organization: Understanding the cellular composition of TCF1+ CD8+ T cell niches in human cancer. Cancer Research 2023, 83: b030-b030. DOI: 10.1158/1538-7445.kidney23-b030.Peer-Reviewed Original ResearchTertiary lymphoid structuresSecondary lymphoid tissuesT cell responsesT cell zonesImmune nicheB cell zonesT cell nicheLymphoid tissueT cellsTumor tissuesEffective anti-tumor T cell responsesAnti-tumor T cell responsesDevelopment of T-cell functionStem-like CD8 T cellsImmune organsCD8 T cell activationCD8 T cell infiltrationTumor-infiltrating T cellsRobust T cell responsesCellular compositionB cell presenceHuman cancersAnti-tumor immunityResponse to immunotherapyCD8 T cells
2020
CD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer
Cardenas M, Prokhnevska N, Jansen C, Master V, Kissick H. CD4 T cell phenotypes differentially modulate the CD8 T cell response in kidney cancer. The Journal Of Immunology 2020, 204: 165.1-165.1. DOI: 10.4049/jimmunol.204.supp.165.1.Peer-Reviewed Original ResearchTumor-infiltrating CD4 T cellsInfiltrating CD4 T cellsCD8 T cell responsesCD4 T cellsAnti-tumor responsesT cell responsesCD8 T cell infiltrationT cellsKidney cancer patientsTumor-specific CD8 T-cell responsesTumor-infiltrating CD8 T cellsSubsets of CD4 T cellsCancer patientsCD8 T cell functionMaster transcription factor Foxp3CD8 T cell differentiationCD4 T cell phenotypeRenal cell carcinoma patientsResponse to immunotherapyCD8 T cellsT cell infiltrationT regulatory cellsT-cell phenotypeCell carcinoma patientsTranscription factor Foxp3
2018
The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer
Jansen C, Prokhnevska N, Kissick H. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer. Urologic Oncology Seminars And Original Investigations 2018, 37: 543-555. PMID: 30446449, PMCID: PMC6513714, DOI: 10.1016/j.urolonc.2018.10.011.Peer-Reviewed Original Research